Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.46 |
| ▸ | GHSR | Q92847 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 2/20 | 0.43 |
| ▸ | MMP9 | P14780 | 2/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.42 |
| ▸ | MGLL | Q99685 | 2/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.41 |
| ▸ | ATXN2 | Q99700 | 2/20 | 0.41 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.40 |
| ▸ | LSS | P48449 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20695498 | 0.90 | SLC6A7 (0.54) | GHSRHSD11B1MGLLSLC6A7SCN9A | |
| SCHEMBL20695282 | 0.88 | FFAR4 (0.46) | HRH3GHSRENPP2ATXN2SLC6A7 | |
| SCHEMBL20695406 | 0.88 | ENPP2 (0.44) | HRH3GHSRHSD11B1MGLLENPP2 | |
| SCHEMBL20695169 | 0.85 | MEN1 (0.47) | HSD11B1EPHX2MGLLSLC6A7 | |
| SCHEMBL20695404 | 0.84 | FFAR4 (0.42) | HTR2BHSD11B1MGLLSCN9ACRBN | |
| SCHEMBL20945342 | 0.82 | MGLL (0.38) | MGLLSLC6A7CRBN | |
| SCHEMBL20695191 | 0.82 | RXRA (0.46) | MGLLSLC6A7 | |
| SCHEMBL20695210 | 0.82 | MAPK1 (0.50) | GHSRSLC6A7CRBN | |
| SCHEMBL20695153 | 0.81 | SLC6A7 (0.42) | MGLLSLC6A7LSS | |
| SCHEMBL20695446 | 0.80 | HPGD (0.47) | HSD11B1MGLLCRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10610520-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-04-07 | — | — | US | disclosed |
| US-20190125728-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-02 | — | — | US | disclosed |
| US-20190125728-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-02 | — | — | US | disclosed |
| EP-3438109-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-02-06 | — | — | EP | disclosed |
| EP-3438109-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190125728-A1 | HETEROCYCLIC COMPOUND | MAG, HTT, ACHE | HRH3 1146/4885GHSR 1876/4885HTR2B 513/4885 |
| US-10610520-B2 | Heterocyclic compound | MAG, HTT, ACHE | HRH3 1146/4885GHSR 1876/4885HTR2B 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.